Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2022-08-11 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于普莱柯生物工程股份有限公司非公开发行股票的会后事项说明及承诺函
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation and commitment letter from Huatai United Securities regarding the post-approval matters of a non-public stock issuance by Pulike Bioengineering Co., Ltd. It references the approval by the China Securities Regulatory Commission, discusses the company's 2022 half-year financial performance, reasons for performance changes, risk disclosures, and the impact on the fundraising project. The document includes detailed financial data for the half-year period and discusses the company's operational and financial status post-approval. It is not the half-year report itself but a post-approval explanatory document related to a capital raising event (non-public stock issuance). The document is lengthy (9683 characters) and contains substantive financial and operational information related to the capital raising and post-approval matters. This fits the category of Capital/Financing Update (CAP) as it provides updates on the company's fundraising activities and related operational impacts after the approval of the non-public stock issuance. It is not an Annual Report, Interim Report, or Regulatory Filing, nor is it a simple announcement or certification. Therefore, the best classification is CAP with high confidence.
2022-08-11 Chinese
立信会计师事务所（特殊普通合伙）关于普莱柯生物工程股份有限公司非公开发行股票会后重大事项的专项说明及承诺函
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation and commitment letter from an accounting firm regarding the post-approval significant matters related to a non-public stock issuance by 普莱柯生物工程股份有限公司. It references regulatory approvals from the China Securities Regulatory Commission (CSRC) and discusses the company's 2022 half-year performance, reasons for performance changes, risk disclosures, and the impact on the fundraising project. The document includes financial data for the half-year period and discusses the company's operational and financial status post-approval. It is not a full annual or interim report but a specialized report related to the non-public stock issuance process, including audit confirmations and compliance statements. The document is about the post-approval matters of a capital raising event and includes audit and regulatory compliance information. This fits best under the category of Capital/Financing Update (CAP), as it deals with the non-public issuance of shares, fundraising, and related disclosures. The document length (9464 characters) and content indicate it is not a mere announcement but a substantive report on the financing event and related performance and compliance matters.
2022-08-11 Chinese
北京德恒律师事务所关于普莱柯生物工程股份有限公司非公开发行股票的会后事项说明及承诺函
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation and commitment letter from a law firm regarding the post-approval matters of a non-public stock issuance by 普莱柯生物工程股份有限公司. It references the approval by the China Securities Regulatory Commission (CSRC) and discusses the company's 2022 half-year performance, reasons for performance changes, risk disclosures, and the impact on the non-public issuance. The document includes financial data and operational analysis but is primarily a legal and compliance statement related to the non-public stock issuance process. It is not an annual or interim report, earnings release, or audit report. It is also not a simple announcement of a report publication but a substantive post-issuance compliance and explanatory document. Given the focus on the non-public stock issuance and related post-approval matters, this fits best under Capital/Financing Update (CAP).
2022-08-11 Chinese
普莱柯关于非公开发行股票会后事项说明及承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the post-issuance matters and commitments related to a non-public stock issuance by the company 普莱柯生物工程股份有限公司. It references regulatory approvals from the China Securities Regulatory Commission and mentions the company's half-year report but does not contain the report itself. The document is short (886 characters) and serves as a disclosure about the stock issuance process and compliance with regulatory requirements. It does not contain detailed financial statements or comprehensive financial data. Therefore, it is best classified as a Capital/Financing Update (CAP) since it relates to the company's financing activities and stock issuance.
2022-08-11 Chinese
普莱柯2022半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年半年度报告' which translates to '2022 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company information, financial indicators, and operational details for the first half of 2022. The content includes comprehensive financial statements, management commentary, and business analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-09 Chinese
普莱柯2022半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official website. The document length is 2116 characters, which is relatively short and appears to be a summary rather than a full report. However, it contains substantive financial data and analysis for the half-year period, not just an announcement or a link to a report. According to the definitions, a half-year or quarterly report with actual financial statements and analysis is classified as an Interim / Quarterly Report (IR). Therefore, despite being a summary, it qualifies as an Interim / Quarterly Report (IR) due to the presence of financial data and analysis for a period shorter than a full fiscal year. H1 2022
2022-08-09 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.